ID   BTLA8.2
AC   CVCL_B7F3
SY   BTLA 8.2
DR   Wikidata; Q112929349
RX   Patent=US9896507;
RX   Patent=US10005839;
RX   PubMed=20693422;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4123.
CC   Monoclonal antibody isotype: IgG1.
CC   Monoclonal antibody target: UniProtKB; Q7Z6A9; Human BTLA/CD272.
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_4032 ! P3X63Ag8.653
CA   Hybridoma
DT   Created: 23-06-22; Last updated: 21-03-23; Version: 3
//
RX   Patent=US9896507;
RA   Olive D., Gondois-Rey F., Serriari N.-E., Pastor S.;
RT   "BTLA antibodies and uses thereof.";
RL   Patent number US9896507, 20-Feb-2018.
//
RX   Patent=US10005839;
RA   Olive D., Pasero C., Gertner-Dardenne J.;
RT   "Antagonist of the BTLA/HVEM interaction for use in therapy.";
RL   Patent number US10005839, 26-Jun-2018.
//
RX   PubMed=20693422; DOI=10.4049/jimmunol.0902487;
RA   Serriari N.-E., Gondois-Rey F., Guillaume Y., Remmerswaal E.B.M.,
RA   Pastor S., Messal N., Truneh A., Hirsch I., van Lier R.A.W., Olive D.;
RT   "B and T lymphocyte attenuator is highly expressed on CMV-specific T
RT   cells during infection and regulates their function.";
RL   J. Immunol. 185:3140-3148(2010).
//